APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-Obesity Prescription Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Anti-Obesity Prescription Drugs Industry Growth and Trends Forecast to 2032

20 December 202593 pages

Choose your research edition.

Industry ResearchAnti-Obesity Prescription Drugs Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-Obesity Prescription Drugs Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Anti-Obesity Prescription Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-Obesity Prescription Drugs Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-Obesity Prescription Drugs Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Anti-Obesity Prescription Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Anti-Obesity Prescription Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Anti-Obesity Prescription Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Anti-Obesity Prescription Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Anti-Obesity Prescription Drugs include Novo Nordisk A/s, Glaxosmithkline, Vivus, Orexigen Therapeutics, F Hoffmann La Roche Ltd, Boehringer Ingelheim, Arena Pharmaceuticals and Alizyme, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Anti-Obesity Prescription Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Anti-Obesity Prescription Drugs market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Anti-Obesity Prescription Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Anti-Obesity Prescription Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Anti-Obesity Prescription Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Anti-Obesity Prescription Drugs Market by Company

Novo Nordisk A/s

Glaxosmithkline

Vivus

Orexigen Therapeutics

F Hoffmann La Roche Ltd

Boehringer Ingelheim

Arena Pharmaceuticals

Alizyme

Anti-Obesity Prescription Drugs Segment by Type

Pediatric

Adult

Anti-Obesity Prescription Drugs Segment by Application

Hospitals Pharmacies

E-commerce

Retail Pharmacies

Anti-Obesity Prescription Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Obesity Prescription Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-Obesity Prescription Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Obesity Prescription Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Anti-Obesity Prescription Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Anti-Obesity Prescription Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Pediatric Table 2. Major Company of Adult Table 3. Global Anti-Obesity Prescription Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Anti-Obesity Prescription Drugs Sales by Type (2021-2026) & (k units) Table 5. Global Anti-Obesity Prescription Drugs Sales Market Share in Volume by Type (2021-2026) Table 6. Global Anti-Obesity Prescription Drugs Sales by Type (2021-2026) & (US$ Million) Table 7. Global Anti-Obesity Prescription Drugs Sales Market Share in Value by Type (2021-2026) Table 8. Global Anti-Obesity Prescription Drugs Price by Type (2021-2026) & (US$/unit) Table 9. Global Anti-Obesity Prescription Drugs Sales by Type (2027-2032) & (k units) Table 10. Global Anti-Obesity Prescription Drugs Sales Market Share in Volume by Type (2027-2032) Table 11. Global Anti-Obesity Prescription Drugs Sales by Type (2027-2032) & (US$ Million) Table 12. Global Anti-Obesity Prescription Drugs Sales Market Share in Value by Type (2027-2032) Table 13. Global Anti-Obesity Prescription Drugs Price by Type (2027-2032) & (US$/unit) Table 14. North America Anti-Obesity Prescription Drugs Sales by Type (2021-2026) & (k units) Table 15. North America Anti-Obesity Prescription Drugs Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Anti-Obesity Prescription Drugs Sales by Type (2021-2026) & (k units) Table 17. Europe Anti-Obesity Prescription Drugs Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Anti-Obesity Prescription Drugs Sales by Type (2021-2026) & (k units) Table 19. Asia-Pacific Anti-Obesity Prescription Drugs Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Anti-Obesity Prescription Drugs Sales by Type (2021-2026) & (k units) Table 21. Latin America Anti-Obesity Prescription Drugs Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Anti-Obesity Prescription Drugs Sales by Type (2021-2026) & (k units) Table 23. Middle East and Africa Anti-Obesity Prescription Drugs Sales by Type (2021-2026) & (US$ Million) Table 24. Anti-Obesity Prescription Drugs Industry Trends Table 25. Anti-Obesity Prescription Drugs Industry Drivers Table 26. Anti-Obesity Prescription Drugs Industry Opportunities and Challenges Table 27. Anti-Obesity Prescription Drugs Industry Restraints Table 28. Global Anti-Obesity Prescription Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Anti-Obesity Prescription Drugs Revenue Market Share by Company (2021-2026) Table 30. Global Anti-Obesity Prescription Drugs Sales by Company (2021-2026) & (k units) Table 31. Global Anti-Obesity Prescription Drugs Sales Share by Company (2021-2026) Table 32. Global Anti-Obesity Prescription Drugs Market Price by Company (2021-2026) & (US$/unit) Table 33. Global Anti-Obesity Prescription Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Anti-Obesity Prescription Drugs Major Company Production Sites and Headquarters Table 35. Global Anti-Obesity Prescription Drugs Company, Product Type & Application Table 36. Global Anti-Obesity Prescription Drugs Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Anti-Obesity Prescription Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Anti-Obesity Prescription Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Anti-Obesity Prescription Drugs Sales by Region (2021-2026) & (k units) Table 41. Global Anti-Obesity Prescription Drugs Sales Market Share in Volume by Region (2021-2026) Table 42. Global Anti-Obesity Prescription Drugs Sales by Region (2021-2026) & (US$ Million) Table 43. Global Anti-Obesity Prescription Drugs Sales Market Share in Value by Region (2021-2026) Table 44. Global Anti-Obesity Prescription Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 45. Global Anti-Obesity Prescription Drugs Sales by Region (2027-2032) & (k units) Table 46. Global Anti-Obesity Prescription Drugs Sales Market Share in Volume by Region (2027-2032) Table 47. Global Anti-Obesity Prescription Drugs Sales by Region (2027-2032) & (US$ Million) Table 48. Global Anti-Obesity Prescription Drugs Sales Market Share in Value by Region (2027-2032) Table 49. Global Anti-Obesity Prescription Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 50. Global Anti-Obesity Prescription Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Anti-Obesity Prescription Drugs Sales by Application (2021-2026) & (k units) Table 52. Global Anti-Obesity Prescription Drugs Sales Market Share in Volume by Application (2021-2026) Table 53. Global Anti-Obesity Prescription Drugs Sales by Application (2021-2026) & (US$ Million) Table 54. Global Anti-Obesity Prescription Drugs Sales Market Share in Value by Application (2021-2026) Table 55. Global Anti-Obesity Prescription Drugs Price by Application (2021-2026) & (US$/unit) Table 56. Global Anti-Obesity Prescription Drugs Sales by Application (2027-2032) & (k units) Table 57. Global Anti-Obesity Prescription Drugs Sales Market Share in Volume by Application (2027-2032) Table 58. Global Anti-Obesity Prescription Drugs Sales by Application (2027-2032) & (US$ Million) Table 59. Global Anti-Obesity Prescription Drugs Sales Market Share in Value by Application (2027-2032) Table 60. Global Anti-Obesity Prescription Drugs Price by Application (2027-2032) & (US$/unit) Table 61. North America Anti-Obesity Prescription Drugs Sales by Application (2021-2026) & (k units) Table 62. North America Anti-Obesity Prescription Drugs Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Anti-Obesity Prescription Drugs Sales by Application (2021-2026) & (k units) Table 64. Europe Anti-Obesity Prescription Drugs Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Anti-Obesity Prescription Drugs Sales by Application (2021-2026) & (k units) Table 66. Asia-Pacific Anti-Obesity Prescription Drugs Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Anti-Obesity Prescription Drugs Sales by Application (2021-2026) & (k units) Table 68. Latin America Anti-Obesity Prescription Drugs Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Anti-Obesity Prescription Drugs Sales by Application (2021-2026) & (k units) Table 70. Middle East and Africa Anti-Obesity Prescription Drugs Sales by Application (2021-2026) & (US$ Million) Table 71. Novo Nordisk A/s Company Information Table 72. Novo Nordisk A/s Business Overview Table 73. Novo Nordisk A/s Anti-Obesity Prescription Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 74. Novo Nordisk A/s Anti-Obesity Prescription Drugs Product Portfolio Table 75. Novo Nordisk A/s Recent Development Table 76. Glaxosmithkline Company Information Table 77. Glaxosmithkline Business Overview Table 78. Glaxosmithkline Anti-Obesity Prescription Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 79. Glaxosmithkline Anti-Obesity Prescription Drugs Product Portfolio Table 80. Glaxosmithkline Recent Development Table 81. Vivus Company Information Table 82. Vivus Business Overview Table 83. Vivus Anti-Obesity Prescription Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 84. Vivus Anti-Obesity Prescription Drugs Product Portfolio Table 85. Vivus Recent Development Table 86. Orexigen Therapeutics Company Information Table 87. Orexigen Therapeutics Business Overview Table 88. Orexigen Therapeutics Anti-Obesity Prescription Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. Orexigen Therapeutics Anti-Obesity Prescription Drugs Product Portfolio Table 90. Orexigen Therapeutics Recent Development Table 91. F Hoffmann La Roche Ltd Company Information Table 92. F Hoffmann La Roche Ltd Business Overview Table 93. F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Product Portfolio Table 95. F Hoffmann La Roche Ltd Recent Development Table 96. Boehringer Ingelheim Company Information Table 97. Boehringer Ingelheim Business Overview Table 98. Boehringer Ingelheim Anti-Obesity Prescription Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. Boehringer Ingelheim Anti-Obesity Prescription Drugs Product Portfolio Table 100. Boehringer Ingelheim Recent Development Table 101. Arena Pharmaceuticals Company Information Table 102. Arena Pharmaceuticals Business Overview Table 103. Arena Pharmaceuticals Anti-Obesity Prescription Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 104. Arena Pharmaceuticals Anti-Obesity Prescription Drugs Product Portfolio Table 105. Arena Pharmaceuticals Recent Development Table 106. Alizyme Company Information Table 107. Alizyme Business Overview Table 108. Alizyme Anti-Obesity Prescription Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 109. Alizyme Anti-Obesity Prescription Drugs Product Portfolio Table 110. Alizyme Recent Development Table 111. North America Anti-Obesity Prescription Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 112. North America Anti-Obesity Prescription Drugs Sales by Country (2021-2026) & (k units) Table 113. North America Anti-Obesity Prescription Drugs Sales Market Share by Country (2021-2026) Table 114. North America Anti-Obesity Prescription Drugs Sales Forecast by Country (2027-2032) & (k units) Table 115. North America Anti-Obesity Prescription Drugs Sales Market Share Forecast by Country (2027-2032) Table 116. North America Anti-Obesity Prescription Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 117. North America Anti-Obesity Prescription Drugs Market Size by Country (2021-2026) & (US$ Million) Table 118. North America Anti-Obesity Prescription Drugs Market Share by Country (2021-2026) Table 119. North America Anti-Obesity Prescription Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 120. North America Anti-Obesity Prescription Drugs Market Share Forecast by Country (2027-2032) Table 121. Europe Anti-Obesity Prescription Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 122. Europe Anti-Obesity Prescription Drugs Sales by Country (2021-2026) & (k units) Table 123. Europe Anti-Obesity Prescription Drugs Sales Market Share by Country (2021-2026) Table 124. Europe Anti-Obesity Prescription Drugs Sales Forecast by Country (2027-2032) & (k units) Table 125. Europe Anti-Obesity Prescription Drugs Sales Market Share Forecast by Country (2027-2032) Table 126. Europe Anti-Obesity Prescription Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 127. Europe Anti-Obesity Prescription Drugs Market Size by Country (2021-2026) & (US$ Million) Table 128. Europe Anti-Obesity Prescription Drugs Market Share by Country (2021-2026) Table 129. Europe Anti-Obesity Prescription Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 130. Europe Anti-Obesity Prescription Drugs Market Share Forecast by Country (2027-2032) Table 131. Asia-Pacific Anti-Obesity Prescription Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 132. Asia-Pacific Anti-Obesity Prescription Drugs Sales by Country (2021-2026) & (k units) Table 133. Asia-Pacific Anti-Obesity Prescription Drugs Sales Market Share by Country (2021-2026) Table 134. Asia-Pacific Anti-Obesity Prescription Drugs Sales Forecast by Country (2027-2032) & (k units) Table 135. Asia-Pacific Anti-Obesity Prescription Drugs Sales Market Share Forecast by Country (2027-2032) Table 136. Asia-Pacific Anti-Obesity Prescription Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 137. Asia-Pacific Anti-Obesity Prescription Drugs Market Size by Country (2021-2026) & (US$ Million) Table 138. Asia-Pacific Anti-Obesity Prescription Drugs Market Share by Country (2021-2026) Table 139. Asia-Pacific Anti-Obesity Prescription Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 140. Asia-Pacific Anti-Obesity Prescription Drugs Market Share Forecast by Country (2027-2032) Table 141. Latin America Anti-Obesity Prescription Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 142. Latin America Anti-Obesity Prescription Drugs Sales by Country (2021-2026) & (k units) Table 143. Latin America Anti-Obesity Prescription Drugs Sales Market Share by Country (2021-2026) Table 144. Latin America Anti-Obesity Prescription Drugs Sales Forecast by Country (2027-2032) & (k units) Table 145. Latin America Anti-Obesity Prescription Drugs Sales Market Share Forecast by Country (2027-2032) Table 146. Latin America Anti-Obesity Prescription Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 147. Latin America Anti-Obesity Prescription Drugs Market Size by Country (2021-2026) & (US$ Million) Table 148. Latin America Anti-Obesity Prescription Drugs Market Share by Country (2021-2026) Table 149. Latin America Anti-Obesity Prescription Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 150. Latin America Anti-Obesity Prescription Drugs Market Share Forecast by Country (2027-2032) Table 151. Middle East and Africa Anti-Obesity Prescription Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 152. Middle East and Africa Anti-Obesity Prescription Drugs Sales by Country (2021-2026) & (k units) Table 153. Middle East and Africa Anti-Obesity Prescription Drugs Sales Market Share by Country (2021-2026) Table 154. Middle East and Africa Anti-Obesity Prescription Drugs Sales Forecast by Country (2027-2032) & (k units) Table 155. Middle East and Africa Anti-Obesity Prescription Drugs Sales Market Share Forecast by Country (2027-2032) Table 156. Middle East and Africa Anti-Obesity Prescription Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 157. Middle East and Africa Anti-Obesity Prescription Drugs Market Size by Country (2021-2026) & (US$ Million) Table 158. Middle East and Africa Anti-Obesity Prescription Drugs Market Share by Country (2021-2026) Table 159. Middle East and Africa Anti-Obesity Prescription Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 160. Middle East and Africa Anti-Obesity Prescription Drugs Market Share Forecast by Country (2027-2032) Table 161. Key Raw Materials Table 162. Raw Materials Key Suppliers Table 163. Anti-Obesity Prescription Drugs Distributors List Table 164. Anti-Obesity Prescription Drugs Customers List Table 165. Research Programs/Design for This Report Table 166. Authors List of This Report Table 167. Secondary Sources Table 168. Primary Sources List of Figures Figure 1. Anti-Obesity Prescription Drugs Image Figure 2. Global Anti-Obesity Prescription Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-Obesity Prescription Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Anti-Obesity Prescription Drugs Sales (2021-2032) & (k units) Figure 5. Pediatric Image Figure 6. Global Pediatric Sales YoY Growth (2021-2032) & (k units) Figure 7. Adult Image Figure 8. Global Adult Sales YoY Growth (2021-2032) & (k units) Figure 9. Global Anti-Obesity Prescription Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Anti-Obesity Prescription Drugs Market Share by Type 2025 VS 2032 Figure 11. North America Anti-Obesity Prescription Drugs Sales Market Share in Volume by Type in 2025 Figure 12. North America Anti-Obesity Prescription Drugs Sales Market Share in Value by Type in 2025 Figure 13. Europe Anti-Obesity Prescription Drugs Sales Market Share in Volume by Type in 2025 Figure 14. Europe Anti-Obesity Prescription Drugs Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Anti-Obesity Prescription Drugs Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Anti-Obesity Prescription Drugs Sales Market Share in Value by Type in 2025 Figure 17. Latin America Anti-Obesity Prescription Drugs Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Anti-Obesity Prescription Drugs Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Anti-Obesity Prescription Drugs Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Anti-Obesity Prescription Drugs Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Anti-Obesity Prescription Drugs Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Hospitals Pharmacies Image Figure 24. Global Hospitals Pharmacies Sales YoY Growth (2021-2032) & (k units) Figure 25. E-commerce Image Figure 26. Global E-commerce Sales YoY Growth (2021-2032) & (k units) Figure 27. Retail Pharmacies Image Figure 28. Global Retail Pharmacies Sales YoY Growth (2021-2032) & (k units) Figure 29. Global Anti-Obesity Prescription Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Anti-Obesity Prescription Drugs Market Share by Application 2025 VS 2032 Figure 31. North America Anti-Obesity Prescription Drugs Sales Market Share in Volume by Application in 2025 Figure 32. North America Anti-Obesity Prescription Drugs Sales Market Share in Value by Application in 2025 Figure 33. Europe Anti-Obesity Prescription Drugs Sales Market Share in Volume by Application in 2025 Figure 34. Europe Anti-Obesity Prescription Drugs Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Anti-Obesity Prescription Drugs Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Anti-Obesity Prescription Drugs Sales Market Share in Value by Application in 2025 Figure 37. Latin America Anti-Obesity Prescription Drugs Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Anti-Obesity Prescription Drugs Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Anti-Obesity Prescription Drugs Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Anti-Obesity Prescription Drugs Sales Market Share in Value by Application in 2025 Figure 41. North America Anti-Obesity Prescription Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 42. North America Anti-Obesity Prescription Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Anti-Obesity Prescription Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Anti-Obesity Prescription Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Anti-Obesity Prescription Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 46. Europe Anti-Obesity Prescription Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Anti-Obesity Prescription Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Anti-Obesity Prescription Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Anti-Obesity Prescription Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 50. Asia-Pacific Anti-Obesity Prescription Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Anti-Obesity Prescription Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Anti-Obesity Prescription Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Anti-Obesity Prescription Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 54. Latin America Anti-Obesity Prescription Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Anti-Obesity Prescription Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Anti-Obesity Prescription Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Anti-Obesity Prescription Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 58. Middle East and Africa Anti-Obesity Prescription Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Anti-Obesity Prescription Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Anti-Obesity Prescription Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Anti-Obesity Prescription Drugs Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Anti-Obesity Prescription Drugs Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Pediatric
  • Adult
Applications
  • Hospitals Pharmacies
  • E-commerce
  • Retail Pharmacies
Companies covered
  • Novo Nordisk A/s
  • Glaxosmithkline
  • Vivus
  • Orexigen Therapeutics
  • F Hoffmann La Roche Ltd
  • Boehringer Ingelheim
  • Arena Pharmaceuticals
  • Alizyme

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Anti-Obesity Prescription Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Anti-Obesity Prescription Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Anti-Obesity Prescription Drugs Market by Type
  6. 1.3.1 Pediatric
  7. 1.3.2 Adult
  8. 1.4 Global Anti-Obesity Prescription Drugs Market Size by Type
  9. 1.4.1 Global Anti-Obesity Prescription Drugs Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Anti-Obesity Prescription Drugs Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Anti-Obesity Prescription Drugs Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Anti-Obesity Prescription Drugs Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Anti-Obesity Prescription Drugs Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Anti-Obesity Prescription Drugs Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Anti-Obesity Prescription Drugs Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Anti-Obesity Prescription Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Anti-Obesity Prescription Drugs Industry Trends
  2. 2.2 Anti-Obesity Prescription Drugs Industry Drivers
  3. 2.3 Anti-Obesity Prescription Drugs Industry Opportunities and Challenges
  4. 2.4 Anti-Obesity Prescription Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Anti-Obesity Prescription Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Anti-Obesity Prescription Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Anti-Obesity Prescription Drugs Price (2021-2026)
  4. 3.4 Global Anti-Obesity Prescription Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Anti-Obesity Prescription Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Anti-Obesity Prescription Drugs Company, Product Type & Application
  7. 3.7 Global Anti-Obesity Prescription Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Anti-Obesity Prescription Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Anti-Obesity Prescription Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Anti-Obesity Prescription Drugs Tier 1, Tier 2, and Tier 3
4 Anti-Obesity Prescription Drugs Regional Status and Outlook
  1. 4.1 Global Anti-Obesity Prescription Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Anti-Obesity Prescription Drugs Historic Market Size by Region
  3. 4.2.1 Global Anti-Obesity Prescription Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Anti-Obesity Prescription Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Anti-Obesity Prescription Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Anti-Obesity Prescription Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Anti-Obesity Prescription Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Anti-Obesity Prescription Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Anti-Obesity Prescription Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Anti-Obesity Prescription Drugs by Application
  1. 5.1 Anti-Obesity Prescription Drugs Market by Application
  2. 5.1.1 Hospitals Pharmacies
  3. 5.1.2 E-commerce
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global Anti-Obesity Prescription Drugs Market Size by Application
  6. 5.2.1 Global Anti-Obesity Prescription Drugs Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Anti-Obesity Prescription Drugs Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Anti-Obesity Prescription Drugs Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Anti-Obesity Prescription Drugs Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Anti-Obesity Prescription Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Anti-Obesity Prescription Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Anti-Obesity Prescription Drugs Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Anti-Obesity Prescription Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Novo Nordisk A/s
  2. 6.1.1 Novo Nordisk A/s Company Information
  3. 6.1.2 Novo Nordisk A/s Business Overview
  4. 6.1.3 Novo Nordisk A/s Anti-Obesity Prescription Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Novo Nordisk A/s Anti-Obesity Prescription Drugs Product Portfolio
  6. 6.1.5 Novo Nordisk A/s Recent Developments
  7. 6.2 Glaxosmithkline
  8. 6.2.1 Glaxosmithkline Company Information
  9. 6.2.2 Glaxosmithkline Business Overview
  10. 6.2.3 Glaxosmithkline Anti-Obesity Prescription Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Glaxosmithkline Anti-Obesity Prescription Drugs Product Portfolio
  12. 6.2.5 Glaxosmithkline Recent Developments
  13. 6.3 Vivus
  14. 6.3.1 Vivus Company Information
  15. 6.3.2 Vivus Business Overview
  16. 6.3.3 Vivus Anti-Obesity Prescription Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Vivus Anti-Obesity Prescription Drugs Product Portfolio
  18. 6.3.5 Vivus Recent Developments
  19. 6.4 Orexigen Therapeutics
  20. 6.4.1 Orexigen Therapeutics Company Information
  21. 6.4.2 Orexigen Therapeutics Business Overview
  22. 6.4.3 Orexigen Therapeutics Anti-Obesity Prescription Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Orexigen Therapeutics Anti-Obesity Prescription Drugs Product Portfolio
  24. 6.4.5 Orexigen Therapeutics Recent Developments
  25. 6.5 F Hoffmann La Roche Ltd
  26. 6.5.1 F Hoffmann La Roche Ltd Company Information
  27. 6.5.2 F Hoffmann La Roche Ltd Business Overview
  28. 6.5.3 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Product Portfolio
  30. 6.5.5 F Hoffmann La Roche Ltd Recent Developments
  31. 6.6 Boehringer Ingelheim
  32. 6.6.1 Boehringer Ingelheim Company Information
  33. 6.6.2 Boehringer Ingelheim Business Overview
  34. 6.6.3 Boehringer Ingelheim Anti-Obesity Prescription Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Boehringer Ingelheim Anti-Obesity Prescription Drugs Product Portfolio
  36. 6.6.5 Boehringer Ingelheim Recent Developments
  37. 6.7 Arena Pharmaceuticals
  38. 6.7.1 Arena Pharmaceuticals Company Information
  39. 6.7.2 Arena Pharmaceuticals Business Overview
  40. 6.7.3 Arena Pharmaceuticals Anti-Obesity Prescription Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Arena Pharmaceuticals Anti-Obesity Prescription Drugs Product Portfolio
  42. 6.7.5 Arena Pharmaceuticals Recent Developments
  43. 6.8 Alizyme
  44. 6.8.1 Alizyme Company Information
  45. 6.8.2 Alizyme Business Overview
  46. 6.8.3 Alizyme Anti-Obesity Prescription Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Alizyme Anti-Obesity Prescription Drugs Product Portfolio
  48. 6.8.5 Alizyme Recent Developments
7 North America by Country
  1. 7.1 North America Anti-Obesity Prescription Drugs Sales by Country
  2. 7.1.1 North America Anti-Obesity Prescription Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Anti-Obesity Prescription Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Anti-Obesity Prescription Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Anti-Obesity Prescription Drugs Market Size by Country
  6. 7.2.1 North America Anti-Obesity Prescription Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Anti-Obesity Prescription Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Anti-Obesity Prescription Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Anti-Obesity Prescription Drugs Sales by Country
  2. 8.1.1 Europe Anti-Obesity Prescription Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Anti-Obesity Prescription Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Anti-Obesity Prescription Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Anti-Obesity Prescription Drugs Market Size by Country
  6. 8.2.1 Europe Anti-Obesity Prescription Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Anti-Obesity Prescription Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Anti-Obesity Prescription Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Anti-Obesity Prescription Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Anti-Obesity Prescription Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Anti-Obesity Prescription Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Anti-Obesity Prescription Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Anti-Obesity Prescription Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Anti-Obesity Prescription Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Anti-Obesity Prescription Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Anti-Obesity Prescription Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Anti-Obesity Prescription Drugs Sales by Country
  2. 10.1.1 South America Anti-Obesity Prescription Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Anti-Obesity Prescription Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Anti-Obesity Prescription Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Anti-Obesity Prescription Drugs Market Size by Country
  6. 10.2.1 South America Anti-Obesity Prescription Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Anti-Obesity Prescription Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Anti-Obesity Prescription Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Anti-Obesity Prescription Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Anti-Obesity Prescription Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Anti-Obesity Prescription Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Anti-Obesity Prescription Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Anti-Obesity Prescription Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Anti-Obesity Prescription Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Anti-Obesity Prescription Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Anti-Obesity Prescription Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Anti-Obesity Prescription Drugs Value Chain Analysis
  2. 12.1.1 Anti-Obesity Prescription Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Anti-Obesity Prescription Drugs Production Mode & Process
  7. 12.2 Anti-Obesity Prescription Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Anti-Obesity Prescription Drugs Distributors
  10. 12.2.3 Anti-Obesity Prescription Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst